Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1991 Jan;20(1):50-65.
doi: 10.2165/00003088-199120010-00004.

Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites

Affiliations
Review

Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites

J V St Peter et al. Clin Pharmacokinet. 1991 Jan.

Abstract

The disposition of phenazone (antipyrine), a low extraction compound with low protein binding, is known to be altered in the presence of various types of hepatic dysfunction. As such, its pharmacokinetics may be useful in the objective characterisation of altered liver function. Understanding the known effects of various liver disease states upon the disposition of this probe may provide insight into future applications. This article provides a review of background information about normal plasma phenazone pharmacokinetics, urinary metabolite disposition and tabulations of reported total body clearances of the drug in the presence of cirrhosis, fatty liver, hepatitis and cholestasis in humans. An estimate is made of the sensitivity and specificity of phenazone testing for the verification of the presence of cirrhosis based on this compiled literature.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Clin Pharmacol. 1989 Mar;29(3):272-7 - PubMed
    1. Br J Clin Pharmacol. 1979 Dec;8(6):529-37 - PubMed
    1. Clin Pharmacol Ther. 1979 Sep;26(3):275-86 - PubMed
    1. Clin Pharmacol Ther. 1975 Sep;18(3):259-72 - PubMed
    1. Clin Pharmacokinet. 1980 May-Jun;5(3):263-73 - PubMed